Kenya - inglese - Pharmacy and Poisons Board

svizera labs private limited turma india - rifampicin 150/ isoniazid 75 tablets - orodispersible tablet - rifampicin 150/ isoniazid 75 tablets - various

Kenya - inglese - Pharmacy and Poisons Board

svizera labs pvt ltd turbhe,navi mumbai - rifampicin 150/ pyrazinamide 400/ isoniazid 75/… - tablet - rifampicin 150/ pyrazinamide 400/ isoniazid 75/… - various

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rifampicin; isoniazid - oral tablet - 150mg ; 100mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rifampicin; isoniazid - oral tablet - 300mg ; 150mg

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin; isoniazid - film-coated tablet - 150 mg/100 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin; isoniazid - film-coated tablet - 300mg/150 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 300 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 600 mg - injection, powder for - excipient ingredients: sodium hydroxide; sodium formaldehyde sulfoxylate - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Singapore - inglese - HSA (Health Sciences Authority)

goldplus universal pte ltd - rifampicin - capsule - rifampicin 150mg